Unresectable or Metastatic HER2-Positive Breast Cancer

Disease

Related News

AstraZeneca's ENHERTU and CALQUENCE Reach Key Regulatory Milestones in Oncology

Feb 26, 2026

AstraZeneca's CALQUENCE received FDA approval as the first all-oral, fixed-duration regimen for chronic lymphocytic leukemia, while the EMA validated the marketing authorization application for ENHERTU in HER2-positive breast cancer treatment.

Enhertu Plus Pertuzumab Approved for First-Line HER2+ Metastatic Breast Cancer

Feb 24, 2026

Enhertu combined with pertuzumab received FDA approval for first-line treatment of HER2-positive metastatic breast cancer, marking the first new treatment in a decade. Real-world data show trastuzumab deruxtecan efficacy is consistent across patient subgroups.